• A poster about Longeveron’s long-term follow-up data from its ELPIS I clinical trial was presented at the 2023 Scientific Sessions of the American Heart Association in November 2023
• The poster showed that 100% of the 10 patients enrolled in the study survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery
• The data supports Longeveron’s ongoing ELPIS II study, which has exceeded its 50% enrollment threshold
• The company believes the long-term follow-up data underscore the potential for Lomecel-B(TM) as a much-needed therapeutic innovation for HLHS patients
• Historical results from outside studies have shown that children with HLHS who are undergoing Stage II surgery have approximately 20% mortality by 5 years of age

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions including hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty has evaluated – and still is evaluating – its lead investigational therapeutic candidate Lomecel-B(TM), an allogeneic, bone marrow-derived medicinal signaling cell (“MSC”) therapy product, in multiple clinical trials.

One of these trials, titled ELPIS I, was a Phase 1, open-label single-arm study whose final results Longeveron announced in September 2021 (https://ibn.fm/iL6z8). ELPIS I was designed to assess the safety and potential efficacy as of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with HLHS during Stage II surgeries at approximately 4 months of age. The study met the primary safety endpoint: no major adverse cardiac events or any treatment-related infections during the first month post-treatment were reported. Moreover, secondary endpoints measured per protocol suggested Lomecel-B(TM) injection may improve patient long-term clinical outcome post-surgery.

While the positive results permitted the transition to a Phase 2 randomized, double-blind, controlled trial, ELPIS II, with enrollment commencing in July 2021 (https://ibn.fm/HuGcD), investigators elected to extend follow-up of the 10 infants after ELPIS I came to its planned end for a total period of five years. More than two years later, at the annual Scientific Sessions of the American Heart Association (“AHA”) held November 11-13, 2023, in Philadelphia, Pennsylvania, a poster about Longeveron’s extended long-term follow-up data was presented. (Additional long-term follow-up is still ongoing in the ELPIS I children.)

The poster, titled Long-term Transplant-free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-based Therapy and authored by Sunjay Kaushal, M.D., Ph.D., the principal investigator of the ELPIS I study, and colleagues, showed that all the 10 children survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery.

The transplant-free survival follow-up on all patients enrolled in the study is ongoing.  Moreover, the average age at the time of the last follow-up visit was 4.5 years, with 2 patients being 5 years of follow-up, according to the company.

“Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants, and reinforce potential survival benefit of Lomecel-B(TM) for patients with HLHS,” commented Joshua M. Hare, Longeveron’s Co-Founder, Chief Science Officer, and Chair of the Board of Directors. “These data represent an additional up to 2 years of follow-up data, which point to the potential of Lomecel-B(TM) in this indication and provide support for our ongoing ELPIS II study, which has exceeded its 50% enrollment threshold. We anticipate completing enrollment in this trial in 2024.”

FDA granted Rare Pediatric Disease Designation (“RPD”), Orphan Drug Designation, and Fast Track designation to Longeveron’s Lomecel-B(TM) for treatment of HLHS. 

HLHS refers to cardiac malformations characterized by underdevelopment or absence of the left ventricle. Before the 1980s, HLHS was associated with 95% mortality within the first month of life. But in the last two decades of the 20th century, there was remarkable progress in the management of children born with HLHS, thanks to the introduction and successful implementation of operative reconstructive procedures, according to a 2000 study (https://ibn.fm/xo0Cy).

These procedures, which are still used to date, are performed in three stages. The final result is a reconstructed heart in which the right ventricle – which ordinarily pumps deoxygenated (venous) blood to the lungs – is now responsible for pumping oxygenated blood to the body through a reconstructed aorta, with venous blood returning directly to the lungs without going through the heart chambers.

While the operative procedures have helped lower mortality, some patients who have undergone surgeries still succumb to HLHS. According to a 2015 study (https://ibn.fm/r54vE), “The highest mortality for infants with HLHS undergoing surgical intervention is with Stage 1 palliation and the interstage period between Stage I and Stage II surgery, both done in the first year of life.”

Furthermore, Kaushal explained, “Historical data collected by the National Heart, Lung, and Blood Institute (‘NHLBI’) has shown that more than 15% of HLHS patients either required a heart transplant or died from their illness 12 months after having undergone Stage 2 surgery. Additional historical data from the NHLBI-sponsored Single Ventricle Reconstruction (‘SVR’) trial – the largest HLHS trial to date, with enrollment of more than 500 patients – shows that patients undergoing Stage II surgery have approximately 15% mortality by year 3 after surgery, which increased to approximately 20% mortality by 5 years.”

These statistics underscore the high unmet need among children with HLHS. Fortunately, the extended follow-up data, which show the 100% survival rate of ELPIS I patients up to 5 years post-treatment, highlight the opportunity for Lomecel-B(TM) as a much-needed therapeutic innovation for this patient group.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

Forward-Looking Statements

Certain statements in this document that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the company’s product candidates, and other positive results; the timing and focus of the company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the company’s product candidates; the company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the company’s ability to attract and retain such personnel; the company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur at all, or that any such transaction will occur on the timelines, in the manner, or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the company’s results and forward-looking statements are disclosed in the company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Reports on Form 10-Q filed with the SEC. The forward-looking statements contained in this presentation are made as of the date of this presentation, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

• Turbo Energy announces strategic partnership with Solar360, a joint venture between two Spanish heavyweights, Repsol and Telefónica España
• Turbo Energy will be the technology provider while Solar360 will be tasked with marketing energy services and installing Turbo Energy’s smart batteries in residential, commercial, and industrial locations in Spain
• The companies are optimistic that this partnership will revolutionize the photovoltaic market in 2024, delivering substantial value to both parties and to consumers

Turbo Energy (NASDAQ: TURB), a photovoltaic energy storage innovator, has started the new year on a high note with a strategic alliance announcement. The company has forged a collaboration with Solar360, a joint venture of Repsol and Telefónica España, signaling a promising beginning for Turbo Energy in 2024. In this partnership, Turbo Energy will supply technology while Solar360 will take on the responsibility of promoting energy services by installing Turbo Energy’s smart batteries in residential, commercial, and industrial locations across Spain (https://ibn.fm/SFkkc).

The two companies join forces in a bid to optimize user savings and ensure energy availability beyond sunny periods. Aligning with their shared objective, this collaboration appears well-matched in the rapidly expanding solar photovoltaic self-consumption sector. Turbo Energy aspires to revolutionize solar energy consumption through innovative AI-driven solutions, enabling consumers to optimize solar potential and cut electricity costs for a more sustainable and energy-efficient future. Solar360 combines Telefónica’s technological and IoT expertise with Repsol’s experience in self-consumption to offer tailored electricity rates and comprehensive solar panel installations for individual customers, communities, and businesses.

Sunbox, Turbo Energy’s flagship product, is the first to be launched by Solar360. As an all-in-one energy solution integrating an inverter, battery, and AI-powered software, Sunbox seeks to manage and store photovoltaic energy efficiently through a user-friendly mobile application. “We are delighted that a market leader like Solar360 has chosen our Sunbox device as a distinctive and innovative product for their value proposition. We are excited about this partnership and believe it will bring value to both sides as well as to a broad variety of consumers,” said Mariano Soria, CEO of Turbo Energy while announcing the partnership.

Sunbox promises to deliver substantial cost savings through an intelligent energy storage system leveraging AI for real-time analysis of diverse data reflecting consumption habits, photovoltaic generation, weather conditions, and applied electricity rates. Solar panels marketed by Solar360 come equipped with an AI-powered battery system, allowing users to manage the energy generated effectively. Users can strategically utilize this stored energy during peak grid demand periods, optimizing cost savings. Additionally, the system enables users to decide the amount of battery reserve for emergencies (https://ibn.fm/1ErEn). Solar360 also commits to providing a photovoltaic production guarantee, which ensures that if the installed system generates less energy than initially estimated in the offer, the company will compensate for the shortfall during the initial year or throughout the amortization period if the customer opts for maintenance.

Turbo Energy monitors users’ energy installations in real-time, tracking both production and consumption. This functionality empowers users to utilize solar-generated energy efficiently during peak consumption hours. In anticipation of adverse weather conditions, the Turbo Energy app ensures that the batteries are fully charged, providing users with a reliable energy source during such events.

Guillermo Barth, CEO of Solar360, does not hide ambitious plans with this partnership. “With this launch, we are revolutionizing the photovoltaic sector with an innovative and distinctive offering in the market, focused on maximizing our customers’ savings. Our goal is to revolutionize the photovoltaic market in 2024,” he concluded.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization
• Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with CNM-Au8 treatment, with further significant improvements in both vision and cognition extending throughout the 96-week LTE
• One of the trial’s key clinical advisors hailed the results as robust and consistent, describing the observed long-term clinical improvements as unprecedented
• Data from both the double-blind trial period and the LTE build a strong case for pursuing CNM-Au8(R) in upcoming Phase 3 studies, said Dr. Benjamin Greenberg, Head of Medicine at Clene

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from the open-label long-term extension (“LTE”) of the VISIONARY-MS trial (https://ibn.fm/5QSDO). This was a double-blind, placebo-controlled Phase 2 clinical trial comprised of participants with chronic optic neuropathy associated with stable relapsing Multiple Sclerosis (“RMS”).

About Multiple Sclerosis

RMS is a disease of the central nervous system in which the body’s own immune system attacks myelin in the brain (the protective sheath that covers and protects nerve fibers). These attacks disrupt communication between the brain and the rest of the body (https://ibn.fm/2oZZU). About 80-90% of people with MS are diagnosed with RMS. A person with this type of MS experiences episodes of new or worsening symptoms, known as relapses, that often occur without warning. The symptoms of RMS include difficulties with vision, trouble with balance, numbness particularly in the feet, weakness, fatigue, difficulty thinking clearly, lack of coordination, need to urinate urgently and frequently, and depression (https://ibn.fm/YPMI8). Several FDA-approved disease-modifying treatments (“DMTs”) for relapsing MS are now available and have been shown to effectively suppress relapses. Despite these drugs, continued disease progression in MS occurs, and no drug currently on the market has been shown to recover function once function has been lost.

Optic neuritis is often associated with MS. Optic neuritis in MS occurs when the optic nerve is damaged by inflammation. The optic nerve carries messages from the eye to the brain and enables our brain to process and interpret what we see. Visual impairments associated with MS can be measured using a special eye chart in which grayed-out letters appear on a white background. The number of letters a person can accurately identify on the eye chart is a measure of low contract letter acuity.

VISIONARY-MS Trial

In order to help MS patients, Clene initiated the VISIONARY-MS trial to investigate the protection or improvement of neurological function following the administration of the company’s CNM-Au8(R) as a potentially remyelinating and neuro-reparative treatment. 92% of all participants in the trial continued the use of highly effective immunomodulatory disease-modifying therapies as background standard of care. As part of the study, participants drank a dose of CNM-Au8 (15 or 30 mg) or placebo daily over 48 weeks.

The trial’s primary outcome was low contrast visual acuity (“LCLA”), an assessment of visual function, or how well people living with optical neuritis caused by their MS can see. Global neurological improvement, measured by modified Multiple Sclerosis Functional Composite (“mMSFC”), which is comprised of assessments for vision, cognition (working memory and processing speed), fine motor dexterity, and walking speed, was the secondary outcome.

Long-Term Open-Label Extension

After completion of the 48-week treatment period, study participants were offered the opportunity to continue receiving CNM-Au8 30 mg for up to nearly two additional years in the LTE. Most placebo participants chose to participate and transitioned to CNM-Au8 for the LTE. Clene announced topline results from the double-blind period of VISIONARY-MS in Q3 2022, and then a few weeks ago announced results from the LTE, which covered assessments conducted through the total of week 144 (35 months after the initial randomization). The company reported analyses for the modified intent to treat (“mITT”) population that included all study participants with valid clinical data.

The results from the LTE included:

• Statistically significant (p < 0.0001) progressive vision improvement as measured by LCLA through week 144 as compared to the original randomization baseline
• Statistically significant (p < 0.0001) progressive cognitive improvement as measured by the Symbol Digit Modality Test (“SDMT”) through week 144 as compared to the original randomization baseline

According to these trial data, placebo patients who transitioned to CNM-Au8 during the LTE showed significant improvements (compared to the original baseline in LCLA and SDMT) after switching to active drug that were consistent with the increases observed in participants originally randomized to CNM-Au8. Moreover, Clene reported that the improvements demonstrated during the initial 48-week treatment period were maintained in the LTE for the timed 25-foot walk test (“T25FWT”), a part of the mMSFC that assessed walking speed, and the nine-hole peg test (“9HPT”), a part of the mMSFC which is used for assessing upper extremity function.

“These observed long-term clinical improvements for participants with stable disease, over and above background immunomodulatory disease-modifying therapy, are unprecedented,” shared Professor Michael Barnett, one of the trial’s key clinical advisors. “The data show clear overall improvements in vision and cognition for participants treated for nearly three years from randomization. Importantly, these results were robust and consistent. Positive impacts on disease progression and the potential to at least partially reverse established disability, if confirmed in a larger study, represent a major therapeutic leap for patients with MS.”

According to Benjamin Greenberg, M.D., Head of Medicine at Clene, the data from the 48-week double-blind period and the 96-week LTE continue to strongly support efforts to pursue CNM-Au8 in upcoming Phase 3 studies. “Clinically significant improvement is rarely seen in MS patients and this trial provides evidence of CNM-Au8’s potential to improve function in this population. Clene is currently reviewing these data with prospective pharmaceutical partners interested in MS,” added Greenberg.

Clene expects to present the full clinical results for the LTE at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) Forum scheduled for February 29 – March 2, 2024, in West Palm Beach, Florida.

The gold nanocrystal suspension, CNM-Au8, is an investigational first-in-class therapy with neuroprotective and neuroreparative properties attributed to the nanocrystals’ ability to catalytically improve energetic metabolism in central nervous system cells. Clene is currently developing CNM-Au8 as a disease-modifying treatment for people living with Amyotrophic Lateral Sclerosis (“ALS”), Parkinson’s Disease, and MS.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• CMS forecasts enrollment in Medicare Advantage programs will increase from 31.6 million in 2023 to 33.8 million in 2024
• Astiva Health recently expanded into three Southern California counties, resulting in the company reaching the 10,000-member milestone mark
• Astiva is committed to reshape healthcare delivery, increased access to quality healthcare

In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success in, Astiva company recently reached a key milestone, surpassing the 10,000-member mark (https://ibn.fm/bQ6jM).

“Enrollment in Medicare Advantage is projected to increase from 31.6 million in 2023 to 33.8 million in 2024,” stated a release from the Centers for Medicare and Medicaid Services (“CMS”) (https://ibn.fm/b5H40). “The projected Medicare Advantage enrollment in 2024 will represent approximately 50% of all people enrolled in Medicare, compared to approximately 48% for 2023.”

The press release went on to quote CMS deputy administrator and director of the Center for Medicare Meena Seshamani, MD, PhD, who said: “Today’s release shows that, as expected, people with Medicare will continue to have robust options and stable benefit offerings in the MA market.”

Astiva is one of the companies committed to providing those robust and stable offerings to a growing number of people looking for the best Medicare options. Reaching the 10,000-member milestone — a substantial increase from Astiva’s 4,700 members in September 2023 — came in part from the company’s recent strategic expansion into the California counties of Los Angeles, Riverside, and San Bernardino. According to the company, the expansion, which went into effect on Jan. 1, 2024, marks a pivotal moment in Astiva Health’s mission to reshape healthcare delivery and increased access to quality healthcare for a diverse range of individuals in Southern California.

“Astiva Health’s rapid growth to over 10,000 members reflects our commitment to providing personalized and culturally responsive healthcare,” said Astiva Health cofounder and CEO Dr. Tri T. Nguyen. “Our expansion into these three counties has not only allowed us to serve a wider community but also to deepen our impact in meeting the unique healthcare needs of our members.”

Astiva is working to achieve its goal of redefining the standards of personalized and comprehensive healthcare by focusing on improving member services, comprehensive medical care, prescription drugs, and great supplemental benefits. In addition, the company’s commitment to offer multilingual solutions and educational resources means that its members experience care that is both effective and culturally sensitive.

“This membership increase is a testament to Astiva Health’s robust and member-centric approach, which prioritizes building lasting relationships and addressing the unique needs of its members,” the company states. “It also signifies the trust and confidence that the community places in Astiva Health as their healthcare provider.”

Astiva Health is a fast-growing MAPD health plan committed to redefining the standards of personalized and comprehensive healthcare. With a mission to elevate the well-being of individuals, Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members.

The organization prioritizes a culturally responsive approach to healthcare and is dedicated to serving the underserved population, not only fulfilling a critical societal need but also positioning the company to tap into a market segment with significant growth potential. By addressing the diverse healthcare needs of its members, Astiva Health aims to create lasting relationships and contribute to the overall well-being of the communities it serves.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Traditional investors often hold onto real world assets (“RWAs”) with the expectation that their risk factors are known and manageable, while avoiding digital assets because of potential volatility and uncertainty about what actually underpins their risk factors
• Utah-based Diamond Lake Minerals Inc. is building a vertically integrated portfolio of noteworthy subsidiaries that will be infused with security token offerings as digital assets bridged to RWAs
• DLMI is working in conjunction with the U.S. Securities and Exchange Commission, SEC-registered digital asset exchange INX, to provide heightened security to digital offerings
• DLMI’s portfolio will include industry-agnostic holdings that span real estate, wireless technology, and entertainment — offering investors a variety of potential opportunities directly connected to real world assets

Salt Lake City-based Diamond Lake Minerals (OTC: DLMI) is dedicated to providing modern investors with a bridging strategy for accessing meaningful digital assets as a healthy part of their investment portfolios.

Digital assets can be discouraging to traditional investors comfortable with putting their money into established real assets that don’t appear to have the amount of risk and volatility associated with traditional digital assets. Nevertheless, the growing market acceptance of digital assets and the sometimes robust profits that digital assets return can be increasingly appealing to those who put serious thought into their investment strategies.

Diamond Lake’s mission builds on the belief that digital assets are worth having so long as they’re operating within a regulated environment. DLMI has partnered with the U.S. Securities and Exchange Commission’s registered security token exchange INX to provide a framework that adheres to guidelines set by U.S. regulators to create a much greater sense of confidence to all market participants.

Diamond Lake’s approach is to build a vast portfolio of vertically integrated subsidiaries in an industry-agnostic manner, infusing each holding with a security token offering (“STO”) so that investors in their real-asset subsidiaries can simultaneously enjoy the benefits of an associated digital asset.

Security Tokens Should Not Be Confused With Tokenized Securities

Tokenized securities simply take the long-standing concept of securities investment and add additional conveniences associated with blockchains (such as improved settlement, greater transparency, more flexibility, and a broader reach). Security tokens, such as those offered by DLMI, share characteristics with securities but they are a new concept, They are created on-chain, for on-chain purposes, enabling new forms of financing, user engagement, investor reward and project governance on rails that didn’t exist until a few years ago. They key, however, has been the need for regulatory clarity, as industry magazine CoinDesk has pointed out (https://ibn.fm/1dY27).

Diamond Lake’s partnership with INX takes the regulatory concerns out of the STO investment.

“There’s been great wealth created with these other crypto types of meme coins and other types of digital assets that don’t operate in a regulatory environment but you look at some of those projects and you have no idea who runs those projects, who built those projects. We don’t even know who built Bitcoin, for example, there’s no definitive person that actually designed and put that in the market,” Brian J. Esposito, DLMI CEO, said in a Jan. 31 interview with Proactive Investors (https://ibn.fm/ELJ7W).

“You look at the wealth of the world that’s in these types of crypto currencies — I love that it gives people the ability to create wealth, but it scares me that there’s so much money there that’s not protected by people or for people and by regulatory,” he added. “From our framework and our guidelines, here’s a way to be in that space; here’s a way to do it, what we believe is … a way to bring traditional securities, which is stocks and bonds, into a vehicle like ours.”

Esposito also addressed some of the potential types of subsidiaries DLMI could acquire, create or build.

“For us, we see things like digital, fractional ownership in physical gold and silver, we see real estate has great potential opportunities, we see great business models like in the wireless technology space — anything that’s a really good asset for our balance sheet and anything that we can create great profitability and returns for, that’s what we want under our DLMI umbrella,” he said. “We want to always create really safe business transactions. We like to do these things with seasoned entrepreneurs and professionals who’ve got great accounting and regulatory and compliance.”

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• Latest customer is a behavioral health care provider, operating four facilities and an outpatient program, with SOBRsafe’s technology being initially installed in one facility, with greater footprint possible
• SOBRsafe’s next-generation transdermal technology detects and instantly reports the presence of alcohol as emitted through the user’s skin. No breath, blood, or urine sample is required
• SOBRsafe’s technology is geared toward behavioral health, judicial and consumer markets, and for licensing and integration

SOBRsafe (NASDAQ: SOBR), a provider of transdermal alcohol detection technology that provides advanced screening and monitoring solutions for the behavioral health and justice industries, recently announced that the company’s game-changing products are gaining momentum – with a fourth behavioral health care provider signing with SOBRsafe. The behavioral health care provider (name withheld for patient privacy considerations) operates four facilities and an outpatient program. The provider will initially install SOBRcheck(TM) in one facility for point-of-care screening and is evaluating the technology for expansion into its remaining facilities. The customer also plans to evaluate the wearable SOBRsure(TM) band for continuous monitoring in an outpatient scenario (https://ibn.fm/tjpHD).

“This customer is consistent with our approach to the behavioral health market – sign providers with multiple uses for our technology, prove its efficacy, and expand within the account,” SOBRsafe chairman and CEO Dave Gandini said. “We are proud of our progress within behavioral health, and we believe that these foundational customer commitments could accelerate industry adoption.”

SOBRsafe’s next-generation transdermal technology detects and instantly reports the presence of alcohol as emitted through the user’s skin. No breath, blood, or urine sample is required. SOBRsafe believes its technology is a more efficient, hygienic and connected replacement for traditional breathalyzers in frontline, preventative applications.

SOBRsafe’s full detection product line includes:

SOBRsafe(TM) – a scalable, patent-pending platform for non-invasive alcohol detection, real-time reporting, and historical data aggregation. The company’s mission is to improve behavioral outcomes and help save lives. Its vision is to become the standard for alcohol screening and monitoring.

SOBRcheck(TM) – the company’s stationary identification and alcohol monitoring product, which provides a quick, specific point-of-care test for the presence of alcohol. Using transdermal (touch-based) technology, SOBRcheck verifies user identity and determines the absence or presence of alcohol – with immediate results delivered securely to aid in the efficient management of an existing substance abuse policy.

SOBRsure(TM) – SOBRsure is a transdermal, alcohol-detecting wearable that provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. SOBRsure provides administrators app-based alcohol detection alerts, pinpoint location tracking, and band removal notifications.

SOBRsafe’s technology is commercially available for point-of-care, wearable use, and licensing or integration. SOBRsafe’s technology offers a powerful backend data platform that is humane and passive – geared toward behavioral health, justice, and consumer markets.

Mr. Gandini also recently participated in the virtual Lytham Partners 2024 Investor Select Conference held on February 1, 2024. His participation in the online event included a fireside chat and one-on-one meetings with investors. Anyone interested in the live replay of the event can watch it on the company’s website (https://ibn.fm/1wmGy).

For more information, visit the company’s website at www.SOBRsafe.com. 

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

• Arizona-based rat population control innovator SenesTech is expanding the market for its unique non-lethal, fertility-reduction products by partnering with a sustainable solutions irrigation company to roll out Evolve(TM) soft bait to open field agriculture
• Rodent population increases have been widely reported in the wake of the COVID pandemic, and SenesTech’s solution is easier to distribute than many poisons and doesn’t carry the high risk of unintentionally harming non-target species
• The company has introduced its products in the United States, Hong Kong, the Maldives, and the United Arab Emirates
• SenesTech’s irrigation solutions partner will initially introduce Evolve(TM) to a California dairy and almond operation, with the goal of expanding distribution to its other customers worldwide

Rodent pest control enterprise SenesTech (NASDAQ: SNES) is expanding its unique rat birth control product line through a team-up with a global leader in irrigation solutions to place SenesTech’s soft bait solution into open field agriculture.

SenesTech is rapidly growing, making a name for itself by targeting the spread of rodent populations through the use of a non-lethal method of intervention in conjunction with or instead of the poisons common to the pest control industry. Its original liquid formulation ContraPest(R) showed success in reducing rat depredations, targeting both male and female rats. However, since professional exterminators, a huge market, preferred a semi-solid product, the company introduced its Evolve(TM) soft bait in October, which has been taking off around the world and is now targeting needs in the vast open field agriculture market.

Pest control company Rentokil reported its study “Rise of the Rats” found a single pair of rats could produce nearly a half billion descendants in three years’ time (https://ibn.fm/WDs9t), but SenesTech’s solution works to prevent that kind of a population explosion through a product highly palatable to rats, non-poisonous, and very effective.

The expansion of Evolve(TM) into open field agriculture addresses a challenge to rodent control efforts — poisons can’t be broadcast in the agricultural setting and the use of traps has limited effectiveness and high expense. Evolve(TM), however, uses a compound derived from food ingredients. The company reports its doses are formulated specifically for rats and are too low to affect the fertility of other species, barring the unlikely ingestion in enormous and repeated quantities.

“The Evolve soft bait, with its minimum risk, its reasonable cost, and its proven efficacy, provides a new tool for this widespread market,” SenesTech President and CEO Joel Fruendt stated in the company’s Jan. 8 announcement (https://ibn.fm/y5GCO).

The company’s sustainable irrigation solutions partner will roll Evolve(TM) out to a California dairy and almond growing customer initially, with the goal of ultimately expanding distribution to their customers across the globe.

Rodents are among animals that may damage almost all types of crops grown around the world, including cereal grains, vegetables, cotton, alfalfa, sugar cane, potatoes and tree fruits (https://ibn.fm/YNRj7), showing the opportunity for SenesTech’s Birth Control for Rats(TM) product in agricultural settings. One report states that in Asia alone the amount of grain eaten by rodents would provide enough food to feed 200 million people for a year.

Observed rodent populations have been increasing in North America, further demonstrating the importance of keeping their numbers in check. According to Pest Management Technology’s 2023 “State of the Rodent Control Market,” 60 percent of pest management professionals reported increases in rodent infestations over the past year while another 38 percent reported that infestations held steady in their markets (https://ibn.fm/HalFo).

Some markets have also prohibited the use of commonly used rat poisons because of concerns about incidental exposure to non-target species, further establishing the importance of non-lethal solutions such as SenesTech’s offerings.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• 1st Detect, a wholly owned subsidiary of mass spectrometry company Astrotech, is offering its breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”) in markets that accept ECAC certification
• The TRACER 1000(TM) ETD is designed to outperform ETDs currently used at airports, cargo and other secured facilities, as well as at borders
• Astrotech is working to position its product as the next-generation solution for the ETD market at a time when many of the existing IMS-based ETDs are due for replacement

Keenly watching the developments in the field of explosives and narcotics detection at airports is Astrotech (NASDAQ: ASTC), a mass spectrometry company that, through its wholly owned subsidiary, 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (“ECAC”), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities, and other secured points around the world.

It is powered by the Astrotech Mass Spectrometer (“AMS”) Technology that is inexpensive, smaller, and easier to use when compared to traditional mass spectrometers. The AMS Technology works under ultra-high vacuum, which eliminates competing molecules, resulting in higher resolution and fewer false alarms.

Normally, ETDs are used at the secondary screening stage at airports. They aid in additional examination of passengers following the detection of something on their person during primary screening. An ETD is designed to assess and analyze samples taken by wiping a passenger’s hands, clothes, or belongings with a swab that is subsequently inserted into the detector.

Astrotech nonetheless believes that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (“IMS”). “The company further believes that some IMS-based ETDs have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustrations, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those few explosives of largest concern,” wrote Astrotech in its most recent Form 10-K annual filing (https://ibn.fm/IOTLZ).

Against this backdrop and as many of the tens of thousands of IMS instruments deployed in the field near their end of life and need replacement, Astrotech is working to position its TRACER 1000(TM) product as the next-generation solution for the ETD market. “Based on our near-zero false alarm rate, we believe that the TRACER 1000(TM) improves checkpoint efficiency and passenger throughput by reducing the need for time-consuming and invasive secondary screenings that cost airports millions in lost merchandise and food sales,” said Thomas B. Pickens III, Chairman and CEO of 1st Detect, in a May 2023 news release announcing a significant purchased order for its next-generation solution (https://ibn.fm/vz6Op).

Astrotech is currently offering the TRACER 1000(TM) to countries that accept ECAC certification while awaiting Transportation Security Administration (“TSA”) certification. Last year, the company received a 17-unit order to deploy the TRACER 1000(TM) ETDs in Europe and another significant purchase order for seven detectors to be deployed in a European airport in Romania (https://ibn.fm/8pCN3).

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

• SuperCom, a global leading provider of digital identity and tracking solutions, is highlighting its electronic monitoring solutions for domestic violence and stalking prevention, with January marking the twentieth annual National Stalking Awareness Month
• In 2023 alone, over 3 million people aged 16 and older were victims of stalking
• Stalking has uprooted people’s lives, causing them to leave their jobs, suffer physical and psychological harm, or even lose their life

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity and tracking solutions to governments, is highlighting its electronic monitoring (“EM”) solutions used for monitoring offenders and domestic violence prevention. These solutions have proven effective in lowering subsequent tracking offenses and protecting victims. It comes in the wake of the ongoing conversation on stalking, coupled with the growing cases of stalking victims, even as this month of January marks the twentieth annual National Stalking Awareness Month (“NSAM”) (https://ibn.fm/sevvH).

January is dedicated to recognizing, taking action, and responding to the severe crime of stalking, which in 2023 affected over 3 million people aged 16 and older in the U.S. alone (https://ibn.fm/T7J7y). This cuts across stalking in person and online and has forced people to uproot their lives, leave their jobs, suffer physical and psychological harm, or even lose lives. According to Olivia Duffy, a victim advocate at Naval Station Mayport, stalking can show up in many forms, including tracking a person’s location, unwanted communication, harassing an individual, property damage, physically following a person, spreading rumors, or even posting or sharing threats (https://ibn.fm/ThofM).

In recent months, there have been cases of victims killed by their stalkers, including those working in the military, as was the case with Brittney Mitchell, who was shot and killed by her husband. The latter was abusive, and Mitchell resorted to divorcing him. She even filed for a restraining order but was still stalked and killed by her husband. It is but one of the many such terrible instances. Unfortunately, many victims never get justice since, according to Duffy, “You really have to have an offender that has to almost be caught in the process.”

SuperCom understands these challenges and seeks to address them using its EM solutions. Its proprietary electronic monitoring technology has proven to enable customers and criminal justice agencies to detect unauthorized movements of people, vehicles, and other monitored objects, ultimately guaranteeing the safety of stalking victims and holding offenders accountable. The company’s monitoring solutions support various programs such as:

• GPS Monitoring 
• House Arrest
• Domestic Violence Prevention
• Inmate Monitoring
• Alcohol Monitoring
• Rehabilitation Services

SuperCom’s solutions have been tried and proven in the field, with various governments around the world adopting them, displaying their effectiveness and functionality. In 2023, the government of Finland also adopted SuperCom’s solutions for its domestic violence monitoring program with an aim to safeguard victims and proactively prevent domestic violence (https://ibn.fm/CvrqC). In the U.S., the company recently secured a new contract with a prominent Kentucky-based service provider, aiding in the company’s expansion into this lucrative market (https://ibn.fm/quCYC).

As the company continues to push for its products, it is carving out a greater market share in the growing electronics monitoring solutions market. This market is expected to post a CAGR of 10.8% between 2021 and 2026. It also expects to tap into the global cybersecurity market, projected to grow from $173.5 billion in 2022 to $266.2 billion by 2027. Most importantly, it looks to protect the millions of domestic violence and stalking victims worldwide and hold offenders accountable.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• An internationally recognized expert on security issues, Secretary Nielsen brings a depth of knowledge and expertise on policy, strategy and operations
• She is steeped in emerging technologies, including artificial intelligence (“AI”) and quantum, and has advised technology companies of all sizes
• Her appointment to the company’s board of directors highlights governments’ rapidly accelerating interest and investment in today’s quantum technology

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the addition of Kirstjen Nielsen, former Secretary of the U.S. Department of Homeland Security, to the company’s board of directors. This board appointment highlights governments’ rapidly accelerating interest and investment in today’s quantum technology (https://ibn.fm/Wx95O). D-Wave is continuing to drive increasing enterprise and government adoption of quantum technology.

Secretary Nielsen is internationally recognized and a proven leader on security issues critical to the United States of America’s highest priorities, including enterprise risk, resiliency, cybersecurity, and emerging threats. She has in-depth knowledge of emerging technology policy, including AI and quantum, and has advised technology companies, from startups to Fortune 100 corporations.

Secretary Nielsen said quantum computing has the potential to transform the way governments and businesses tackle operational complexities, and she believes that D-Wave is leading this evolution. “From the amazing technology developments on the horizon to the impressive scientific results I’ve seen, D-Wave is well-positioned to capitalize on its unique strengths as it ushers in this new era of computing,” Nielsen added. “I’m looking forward to helping the company during this pivotal time.”

Secretary Nielsen’s experience includes policy, strategy, and operations, giving her a unique perspective and influencing her position on the importance of stakeholder engagement. Her history of working with governments to utilize emerging technologies as a force multiplier is important for today’s quantum computing, as it has advanced to tackling real-world problems. D-Wave’s expertise in this area is showcased in its Customer Success Stories (https://ibn.fm/7Pw2a).

D-Wave customers include blue-chip industry leaders like Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin. D-Wave also owns one of the industry’s largest quantum computer intellectual property portfolios, with more than 210 issued U.S. patents.

Beyond her work with the Department of Homeland Security, Secretary Nielsen has held various domestic and international government roles. She has served on the White House Homeland Security Council, helped create and run the TSA, and led the World Economic Forum’s Global Agenda Council on Risk and Resilience. Secretary Nielsen is a member of the State Bar of Texas, holds a B.S. in foreign service from Georgetown University and a J.D. from the University of Virginia’s School of Law, and has practiced transactional law.

D-Wave CEO Dr. Alan Baratz said this is a transformative time in quantum computing, as governments and businesses increasingly recognize the near-term value today’s quantum solutions can deliver. “It’s also a transformative time for D-Wave, and we’re incredibly excited to have Secretary Nielsen join the board to help the company accelerate quantum adoption and explore quantum’s impact on AI and machine learning. As an attorney, public servant, and US and international policy expert, she will bring valuable perspectives to the D-Wave board,” Baratz added.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of quantum computing, D-Wave’s positioning in the industry, and the perspectives that Sec. Nielsen will bring to the D-Wave board. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risk that Sec. Nielsen may leave the D-Wave board sooner than expected; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of D-Wave’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that that company is unable to secure or protect its intellectual property; volatility in the price of its securities; the risk that its securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.